Guangzheng Eye Care has unveiled a 2026 restricted stock incentive plan, proposing to grant no more than 1.5 million shares to 103 directors, senior executives, and core staff. The performance assessment target is to return to net profit in 2026, with net profit of no less than 20 million yuan in 2027. The company's ophthalmology business contributes nearly 90 percent of revenue, with refractive and cataract projects achieving revenues of 270 million yuan and 261 million yuan respectively, and gross margins holding at 45.79 percent and 47.26 percent. Guangzheng Eye Care stated it is currently in a critical period of loss recovery and will deepen refined operations and digital-intelligent transformation to improve quality and efficiency.
Guangzheng Group Co LtdLaunches restricted stock incentive plan with performance targets aiming for 2026 turnaround and 2027 net profit of at least 20 million yuan.